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The study investigated hypoxia-associated markers (HIF-2a, Epo, Epo-R, Glut-1 and VEGF) along with Ki-67 in a gastric carcinogenesis
model, and the prognostic significance of hypoxia-inducible factor (HIF)-2a in surgically treated gastro-oesophageal cancer. Protein
expression was examined using immunohistochemistry on formalin-fixed, paraffin-embedded biopsies of normal mucosa (n¼20),
Helicobacter pylori-associated gastritis (n¼24), intestinal metaplasia (n¼24), dysplasia (n¼12) and intestinal (n¼19) and diffuse
(n¼21) adenocarcinoma. Relationships between HIF-2a expression and prognosis were assessed in resection specimens from 177
patients with gastric and gastro-oesophageal junction adenocarcinoma. Expression of all markers increased with progression along the
gastric carcinogenesis sequence (P¼0.0001). Hypoxia-inducible factor-2a was expressed in 63% of 177 resection specimens and at a
high level in 44%. The median overall survival in patients with HIF-2a-expressing tumours was 22 (95% CI 18 26) months, whereas
those with HIF-2a-negative tumours had a median survival of 37 (95% CI 29 44) months (P¼0.015). Hypoxia-inducible factor-2a
had no independent prognostic significance in multivariate analysis. In view of the lack of independent prognostic significance, HIF-2a
has no role as a routine prognostic indicator. However, the high expression of HIF-2a suggests that it may be of value as a potential
therapeutic target.
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Gastric and oesophageal cancers are among the most common
malignancies worldwide and contribute significantly to global
cancer mortality (Parkin et al, 2001). To improve the diagnosis and
prognosis of gastric and gastro-oesophageal cancer, it is important
to fully understand the molecular mechanisms underlying
carcinogenesis. The well-described premalignant sequences of
these tumour types make them ideal to study and explore potential
molecular mechanisms of carcinogenesis by immunohisto-
chemistry. Histologically, gastric cancers can be classified into
two types: diffuse and intestinal. For the development of intestinal
gastric cancer, a multistep process involving a progressive cascade
of molecular and morphological changes has been proposed by
Correa (2004). Diffuse tumours have no known premalignant
precursor lesions. For both types of tumour, the carcinogenesis
process is believed to be initiated by Helicobacter pylori infection
and the risk of gastric cancer development has been related to
H. pylori strain type, other environmental factors, host genetic
factors and immune-related polymorphisms (Nardone et al, 2004).
Tumour hypoxia is a key factor driving the development of
malignancy, and the master regulatory protein in the response of
cells to changing oxygen levels is the hypoxia-inducible factor
(HIF). Researchers have hypothesised that hypoxia plays a primary
role in the carcinogenesis process. Studies have shown progres-
sively increased HIF-1a expression in breast (Bos et al, 2001), skin
(Costa et al, 2001) and cervical (Acs et al, 2003) cancer
development. More recently, we have shown increased expression
of HIF-1a in gastric cancer development (Griffiths et al, 2007b)
and in adenocarcinoma vs dysplasia in the Barrett’s oesophageal
cancer sequence (Griffiths et al, 2007a). Hypoxia-inducible factor-
1a is a key mediator of transcription and upregulates genes
involved in a variety of processes: vascular endothelial growth
factor (VEGF); erythropoietin (Epo) and its receptor (Epo-R),
which regulates erythropoiesis by stimulating the growth and
differentiation of red blood cell precursors (Yasuda et al, 2003;
Ratcliffe, 2007). Erythropoietin and its receptor (Epo-R) are
expressed in a number of cancers and are involved in breast
(Acs et al, 2002), endometrial (Acs et al, 2004), melanoma (Kumar
et al, 2005) and prostate (Feldman et al, 2006) tumorigenesis.
Recently, a number of proteins have been identified that are
closely related to HIF-1a and control the transcription of hypoxia-
regulated genes in a similar way (HIF-2a and HIF-3a) (Calzada and
del Peso, 2007). A study in non-small cell lung cancer showed that
HIF-2a expression was related to a poor outcome whereas HIF-1a
expression was not (Giatromanolaki et al, 2001). Another study
showed a predominant role of HIF-2a over HIF-1a in the
regulation of the transcriptional response to hypoxia in renal cell
carcinoma (Sowter et al, 2003). These findings raise the possibility
of tissue-specific differences in the relative importance of HIF
proteins in determining tumour progression and prognosis. We
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shave previously shown that HIF-1a is involved in gastric
carcinogenesis and invasive edge tumour expression is associated
with an adverse prognosis (Griffiths et al, 2007b). Hypoxia-
inducible factor-2a expression, however, has not yet been assessed
as a prognostic marker in gastro-oesophageal cancer.
The hypothesis underlying the research is that hypoxia plays a role
in the aetiology and prognosis of gastro-oesophageal cancer. The
specific goals of the research were to investigate whether the
expression of hypoxia-associated proteins increases along the gastric
carcinogenic sequence. Three hypoxia-associated markers were
selected that have not been assessed in gastric carcinogenesis:
HIF-2a, Epo and Epo-R. Although studied previously, VEGF and
Glut-1 were also studied. The widely investigated Ki-67 was included
as a comparator. The expression of the proteins was assessed using
immunohistochemistry in paraffin-embedded material representing
the gastric carcinogenesis sequence. A further aim was to assess the
prognostic value of HIF-2a expression in surgically treated gastric
and gastro-oesophageal cancer patients.
PATIENTS AND METHODS
Tissue specimens
The study was approved by the South Manchester Ethics
Committee. Tissues were obtained from the Department of
Histopathology, South Manchester University Hospitals NHS
Trust. Formalin-fixed endoscopic gastric biopsy samples obtained
were of normal gastric mucosa (n¼20), H. pylori-associated
gastritis (n¼20), intestinal metaplasia (n¼20), epithelial dys-
plasia (n¼12) and intestinal (n¼19) and diffuse (n¼21) gastric
adenocarcinoma. Four of the biopsies had both H. pylori-infected
mucosa and intestinal metaplasia. Haematoxylin and eosin slides
were reassessed by a consultant pathologist (SP) to ensure correct
classification. All cases of H. pylori-associated gastritis showed
significant numbers of organisms. The epithelial dysplasia group
was classified as low- (n¼6) or high- (n¼6) grade. Intestinal
metaplasia was present in 6 of the 12 dysplasia biopsies.
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Figure 1 Representative photomicrographs of HIF-2a, VEGF, Epo, Epo-R immunohistochemistry in the gastric cancer progression sequence.
A(I)¼intestinal adenocarcinoma; A(D)¼diffuse adenocarcinoma; Dys¼dysplasia; Epo¼erythropoietin; Epo-R¼erythropoietin receptor; HIF-2a¼
hypoxia-inducible factor-2a; HpG¼H. pylori gastritis; IM¼intestinal metaplasia; N¼normal mucosa; VEGF¼vascular endothelial growth factor.
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sSurgically treated patients
A retrospectively compiled database was established of 251
consecutive patients with primary gastric and gastro-oesophageal
junction tumours who underwent surgery at the South Manchester
University Hospitals NHS Trust between 1995 and 2004. The
Siewert classification was used to classify gastro-oesophageal
junction tumours (Siewert and Stein, 1998). Patients who had
either Siewert type I gastro-oesophageal tumours (n¼22), neo-
adjuvant therapy (n¼31), emergency surgery (n¼1), completion
gastrectomy (n¼6) or died after surgery (n¼25) were excluded
from the study. The study group therefore comprised 177 patients
(125 men) with a median age of 68 (range 49–85) years. There
were 76 Siewert type II, 21 type III gastro-oesophageal junction
tumours and 80 noncardia gastric cancers. Patients underwent
either partial or subtotal gastrectomies (n¼45), total gastrectomy
(n¼44), proximal gastrectomy (n¼4) or oesophago-gastrectomy
(n¼84). Selected patients underwent additional surgical resection
of the spleen (n¼21) and spleen with distal pancreas (n¼5). One
hundred and thirteen patients (64%) underwent a potentially
curative resection (R0). Fifty-four patients (31%) had residual
microscopic disease (R1 resection) and 10 patients (6%) had
residual macroscopic disease (R2 resection). After surgery,
patients were followed in the surgical outpatient clinic. Hospital
notes of the patients were reviewed and, if necessary, the local
cancer registry or patient’s general practitioner was contacted to
complete case follow-up.
Immunohistochemistry
Antigen retrieval was carried out by microwaving for 25min in
either 10mM sodium citrate (pH 6.0) or 0.05 M Tris-HCl (Sigma-
Aldrich Ltd., Poole, UK)/1mM EDTA (Sigma) (pH 8.5 or 9.0) buffer
solution. After quenching endogenous peroxidase, nonspecific
binding was blocked using 10% casein solution (Vector Labora-
tories Ltd., Peterborough, UK). The primary antibody was applied
and the sections incubated as described elsewhere (Griffiths et al,
2007a). Mouse or rabbit EnVisionPlus System (Dako, UK) was
used for antigen detection. Identical concentrations of immuno-
globulin IgG1 (Dako Ltd., Ely, UK) from the same species were
used as negative controls. Positive and negative (or low) tissue
controls from gastric, cervical or head and neck cancer with
known staining characteristics were used in each batch.
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Figure 2 Box and whisker plots of each immunohistochemical marker in the gastric carcinogenesis sequence. The box represents 25–75 quartiles with a
median line. The whiskers extend to minimum and maximum values, but exclude outlying and far-out values. A(I)¼intestinal adenocarcinoma;
A(D)¼diffuse adenocarcinoma; Dys¼dysplasia; Epo¼erythropoietin; Epo-R¼erythropoietin receptor; HIF-2a¼hypoxia-inducible factor-2a; HpG¼
H. pylori gastritis; IM¼intestinal metaplasia; N¼normal mucosa; VEGF¼vascular endothelial growth factor.
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sBatch-to-batch variation was assessed by running sections showing
high and low protein expression with each batch. Antibodies were
visualised with 3,30-diaminobenzidine (Dako) and the sections
lightly counterstained with haematoxylin, dehydrated and cover-
slipped.
Scoring
Scoring was performed in a double-blind manner by two
investigators (SAP, SMG). Any disagreement was resolved by
discussion to obtain final scores. Markers (HIF-2a, VEGF, EPO,
EPO-R, Glut-1, and Ki-67) in the carcinogenesis study were scored
using the same scoring system. A score (0–300) was calculated for
each marker by multiplying intensity (none 0, weak 1, moderate 2,
strong 3) with percentage of expression (range 0–100). For the
prognostic study, tumour nuclear HIF-1a and HIF-2a staining was
scored as follows: 0, no staining; 1, o2% staining; 2, 2–10%
staining; 3, 11–29% staining; and 4, 430% staining. Hypoxia-
inducible factor-1a scores were obtained from our previous
research (Griffiths et al, 2007b).
Statistics
Data were analysed using SPSS version 11.5. The Spearman’s rank
test was used to investigate relationships between variables.
Differences in expression levels in the carcinogenesis studies were
assessed using Mann–Whitney and Kruskal–Wallis tests. The
Jonckheere–Terpstra test was used to identify ordered differences
in marker expression. With this test, the null hypothesis is that
distributions do not differ across ordered categories. The w
2 test
was used to correlate tumour HIF-2a expression with clinico-
pathological characteristics.
Survival time was measured as the time from the date of surgery
until death or last follow-up appointment. Overall and cancer-
specific survival were used as end points. At the time of analysis,
51 patients were alive with a median follow-up of 48 (range 13–
118) months and 107 had died of disease with a median time to
death of 14 (range 2–74) months. There were 16 intercurrent
deaths from other causes. Univariate survival analyses were
illustrated using the Kaplan–Meier method. Factors were com-
pared using the Cox proportional hazards model and log-rank
tests. Multivariate survival analysis was performed on factors that
achieved statistical significance in univariate analysis, using the
Cox proportional hazards model to identify independent pre-
dictors of survival. All statistical tests were two-sided at the 0.05
significance level. As adjusting statistical significance depending
on the number of tests performed can create problems (Perneger,
1998), no allowance was made for multiple testing.
RESULTS
Staining
Figure 1 shows photomicrographs of HIF-2a, VEGF, Epo and
Epo-R staining in the gastric cancer progression sequence. Only
Marker n
Percentiles Kruskall–Wallis Jonckheere–Terpstra
25th 50th 75th P 2 Statistic P
HIF-2 118∗ 0 0 38.75 56.2 0.0001 6.9 0.0001
VEGF 119∗ 75 180 285 35.4 0.0001 4.6 0.0001
Epo 118∗ 0 0 50 18.8 0.02 3.6 0.0001
Epo-R 119∗ 90 180 270 37.2 0.0001 6.4 0.0001
Glut-1 119∗ 0 0 0 46.0 0.0001 5.8 0.0001
Ki-67 114∗ 57.75 105 216 71.4 0.0001 8.6 0.0001
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Figure 3 The mean rank score (Kruskall–Wallis test) of each marker in relation to the gastric carcinogenesis sequence. Immunohistochemical score was
calculated from percentage (0–100) multiplied by intensity (0–3) of expression for each marker studied. *Insufficient biopsy tissue for marker scoring in
some sections. The Kruskall–Wallis and Jonckheere–Terpstra test results for each immunohistochemical marker studied in the gastric carcinogenesis
sequence. A(I)¼intestinal adenocarcinoma; A(D)¼diffuse adenocarcinoma; Dys¼dysplasia; Epo¼erythropoietin; Epo-R¼erythropoietin receptor;
HIF-2a¼hypoxia-inducible factor-2a; HpG¼H. pylori gastritis; IM¼intestinal metaplasia; N¼normal mucosa; VEGF¼vascular endothelial growth factor.
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snuclear HIF-2a staining was scored, however, occasional cyto-
plasmic staining was seen. Hypoxia-inducible factor-2a was not
expressed in normal tissue. Low levels of expression were found in
H. pylori gastritis and intestinal metaplasia biopsies. Vascular
endothelial growth factor staining was cytoplasmic. Normal gastric
mucosa showed weak staining mainly in the deep portions of the
crypts that tended to be basal in location, in cytoplasm around the
nucleus. Areas of intestinal metaplasia showed increased staining
compared with normal mucosa and adjacent nonmetaplastic
mucosa within the same biopsy. Erythropoietin staining was
cytoplasmic and predominantly focal in nature; Epo-R was
expressed in cytoplasm and membrane. Inflammatory cells acted
as an internal positive control. Glut-1 staining was cytoplasmic
and/or membranous, and detected only in invasive cancer
biopsies. In normal gastric mucosa, nuclear Ki-67 staining was
present mainly in the cells in the neck region of the gastric pits. In
neoplastic tissue, this normal staining pattern was lost and more
diffuse expression seen. In all cases along the gastric carcinogen-
esis sequence, when specialised gastric body-type cells (chief and
parietal cells) were present in the biopsy, they showed intense
staining for VEGF and Epo-R in a uniform fashion. As the staining
was identical in all cases these areas were not scored.
Expression of markers along the gastric carcinogenesis
sequence
Interobserver agreement for marker scores was highly statistically
significant and consistent for all the markers studied (Po0.0001
for all). With the exception of Glut-1 and VEGF, there were
statistically significant correlations between the expression levels
of the various markers. For example, HIF-2a expression correlated
with VEGF (r¼0.20, P¼0.03), Epo (r¼0.34, Po0.001), Epo-R
(r¼0.46, Po0.001), Glut-1 (r¼0.38, Po0.001), Ki-67 (r¼0.59,
P¼0.59, Po0.001) and also HIF-1a (r¼0.34, Po0.001). Box and
whisker plots (including individual data points) are shown in
Figure 2 and mean rank scores (from the Kruskall–Wallis test
statistics) are plotted in Figure 3. There was a statistically
significant increase in the expression of all markers along the
progression sequence to adenocarcinoma.
Expression of HIF-2a in surgically resected specimens
Tumours tended to show diffuse staining for HIF-2a in almost all
nuclei or negative staining (Figure 1). There was no obvious
association with inflammation, ulceration or infiltrative edge and
location of HIF-2a positive staining. In nine slides, cytoplasmic
staining was present; this was not scored. Focal staining was
identified in some inflammatory cells that acted as an internal
positive control. Five sections (2.8%) had insufficient tissue for
HIF-2a scoring. In 66 sections (37.3%), no HIF-2a immunostaining
was observed. Positive nuclear staining was as follows: o2%
staining in 9 sections (5.1%), 2–10% staining in 13 sections
(7.3%), 11–30% staining in 6 sections (3.4%) and 430% staining
in 78 sections (44.1%). All negative controls showed no
immunoreactivity. No statistically significant relationships were
found between the expression of HIF-1a (Griffiths et al, 2007b) and
HIF-2a (P¼0.31).
HIF-2a expression and clinicopathological features
For correlation with various clinicopathological features, HIF-2a
expression was categorised as negative (score 0) and positive
(scores 1/2/3/4). The distribution of patients according to tumour
HIF-2a expression is shown in Table 1. Hypoxia-inducible factor-
2a-positive tumours were more likely to be diffuse (P¼0.025).
There was also a trend for HIF-2a tumours to have a
more advanced T stage (P¼0.058). No statistically significant
correlations were found between HIF-2a and differentiation, N
stage, M stage, overall TNM stage or R classification.
HIF-2a expression and patient survival
Tumour HIF-2a expression was a statistically significant adverse
prognostic factor (Figure 4 and Table 2). The median overall
survival for patients with tumour HIF-2a expression was 22 (95%
CI 18 26) months, whereas HIF-2a-negative patients had a
median survival of 37 (95% CI 29 44) months (P¼0.015).
Hypoxia-inducible factor-2a expression was more prognostic for
gastric (P¼0.032) than gastro-oesophageal (P¼0.26) tumours
(Figure 4). Other significant factors in univariate survival analyses
were tumour differentiation, T stage, N stage, overall TNM stage
and R classification (Table 2).
The combined effect of tumour HIF-1a (Griffiths et al, 2007b)
and HIF-2a expression was analysed in relation to patient
outcome. Patients with invasive edge HIF-1a- and HIF-2a-
expressing tumours had a poorer overall survival than those with
HIF-1a-negative/focally positive and HIF-2a-negative cancers
(P¼0.006). The median overall survival times were 17 (95% CI
4 30) and 40 (95% CI 32 42) months, respectively. Correspond-
ing figures for cancer-specific survival were 41 and 17 (95% CI
4 30) months (P¼0.007). As for HIF-1a (Griffiths et al, 2007b)
and HIF-2a (Figure 4) alone, the combined adverse effect of
invasive edge HIF-1a and HIF-2a expression was greater for gastric
Table 1 The distribution of patient characteristics according to tumour
expression of HIF-2a (n¼172)
Factor HIF-2a negative HIF-2a positive P*
Differentiation
Well 8 10
Mod 24 41
Poor 34 55 0.84
Lauren type
Diffuse 27 62
Intestinal 39 44 0.025
T stage
T in-situ 03
T1 7 9
T2 27 26
T3 32 64
T4 0 4 0.058
N stage
N0 20 29
N1 37 62
N2 7 13
N3 2 2 0.921
M stage
M0 65 103
M1 1 3 0.58
Overall TNM stage
00 3
I1 41 5
II 23 31
III 27 50
IV 2 7 0.31
R class
R0 46 64
R1 19 33
R2 1 9 0.13
HIF¼hypoxia-inducible factor. *w
2 P-value.
Hypoxia-associated markers in gastro-oesophageal cancer
EA Griffiths et al
969
British Journal of Cancer (2008) 98(5), 965–973 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sthan for gastro-oesophageal junction tumours for both disease-
specific (P¼0.026 vs 0.104) and overall (P¼0.047 vs 0.089)
survival (Figure 5). For example, patients with HIF-1a-negative/
focally positive and HIF-2a-negative gastric cancers had an average
disease-free survival of 81 (95% CI 59 103) months compared
with 25 (95% CI 11 39) months for those with invasive edge
HIF-1a- and HIF-2a-positive tumours. All analyses were repeated
stratifying patients by 0/1 vs 2/3/4 scores. Although qualitatively
similar results were seen, they were not statistically significant.
All factors that achieved statistical significance (Po0.05) in the
univariate analysis were entered into a multivariate analysis.
Neither HIF-2a expression nor HIF-1a/HIF-2a combined had any
independent prognostic significance. Only tumour differentiation,
overall TNM stage and R classification retained significance in
multivariate analysis.
DISCUSSION
All markers studied showed a statistically significant increase in
expression with progression from H. pylori-associated gastritis,
intestinal metaplasia, dysplasia to adenocarcinoma (P¼0.0001). It
must be emphasised, however, that this model does not apply to
gastro-oesophageal junction tumours. Gastro-oesophageal adeno-
carcinomas (Siewert type I and II tumours) arise via a similar
sequence of histopathological events; however, the initiating,
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Figure 4 Hypoxia-inducible factor-2a expression and patient outcome in 172 tumours including noncardia gastric cancers (n¼80) and gastro-
oesophageal junction tumours (n¼92). The first column shows HIF-2a-negative (score 0) vs positive (scores 1/2/3/4) expression and overall survival. For all
tumours (A), gastric cancers (C) and gastro-oesophageal junction tumours (E). Second column shows disease-specific survival. For all tumours (B), gastric
tumours (D) and gastro-oesophageal junction tumours (F). HIF¼hypoxia-inducible factor.
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spromoting and molecular factors are different to gastric cancer
carcinogenesis. Indeed, H. pylori appears to exert a protective role
in these types of tumours (Chow et al, 1998). We have previously
assessed these immunohistochemical markers in a similar model
of oesophageal carcinogenesis (Griffiths et al, 2007a).
Previous studies have shown the importance of Ki-67 expression
and proliferation in the progression of gastric cancer. For example,
Leung et al (2001) showed that proliferation, as measured by Ki-67
expression, was significantly increased in both H. pylori-infected
and intestinal metaplasia biopsy material. Interestingly, they also
found that the apoptotic to proliferation index ratio was
significantly reduced, favouring cellular DNA-damage accumula-
tion and neoplastic progression. Similarly, the role of VEGF and
angiogenesis in the gastric carcinogenesis sequence has been
previously reported. We found similar results to that of Feng et al
(2002), who assessed VEGF expressed by immunohistochemistry.
Our finding that Glut-1 protein is not found in normal gastric
mucosa but only expressed in gastric carcinoma also confirms the
results of others (Younes et al, 1996; Kim et al, 2000; Kawamura
et al, 2001). For example, one study reported no expression of
Glut-1 in normal gastric mucosa, intestinal metaplasia and tubular
adenomas but 30% of 617 gastric carcinomas was positive for the
protein (Kawamura et al, 2001).
Erythropoietin and Epo-R have been shown to be expressed in a
number of cancers and involved in breast (Acs et al, 2002),
endometrial (Acs et al, 2004), melanoma (Kumar et al, 2005),
prostate (Feldman et al, 2006) and Barrett’s oesophageal (Griffiths
et al, 2007a) carcinogenesis. There appear to be no other studies that
have assessed these proteins in gastric carcinogenesis. Both Epo and
Epo-R were expressed in varying degrees in all biopsy types, but
Epo-R was expressed more abundantly. The expression of both
proteins increased from normal tissue through to invasive cancer.
Endogenous Epo is a glycoprotein produced primarily in the adult
kidney in response to hypoxia. Its main function is to regulate erythro-
poiesis by stimulating growth, inhibiting apoptosis and inducing
differentiation of red blood cell precursors (Yasuda et al, 2003).
Hypoxia-inducible factor-2a expression occurred principally as
a late phenomenon. However, there was evidence of expression in
a minority of the earlier premalignant biopsies of H. pylori gastritis
and intestinal metaplasia. Hypoxia-inducible factor-2a expression
has not been studied in models of tumour carcinogenesis except in
our work in the Barrett’s metaplasia–dysplasia–adenocarcinoma
sequence, where we showed that HIF-2a was expressed late in the
sequence and was seen only in dysplasia and adenocarcinoma
(Griffiths et al, 2007a). Recently, the overexpression of HIF-2a in
rat gliomas was shown to have counteracting properties, in which
angiogenesis was induced but reduced growth was also found due
to increased tumour-cell apoptosis (Acker et al, 2005). Hypoxia-
inducible factor-2a expression has also been suggested to be
critical in the carcinogenesis of renal cortical tumours (Kim et al,
2006).
Hypoxia-inducible factor-2a accumulates in the presence of
hypoxia, forms a heterodimer with HIF-1b and binds to hypoxia-
responsive elements. Hypoxia-inducible factor-2a has been shown
to regulate a number of the same hypoxia-inducible genes as
HIF-1a (Hu et al, 2003). However, it is now known that the various
hypoxia-inducible genes vary in their sensitivity to HIF-1a and
HIF-2a (Wang et al, 2005) and therefore different downstream
pathways can be preferentially activated (Hu et al, 2003; Sowter
et al, 2003). The classical ‘hypoxic’ expression of HIF-2a in tumour
sections was not found in our study as there was no association
with necrosis or distance from blood vessels. This may suggest
nonhypoxic activation. However, unlike HIF-1a, the nonhypoxic
activation of HIF-2a has not been confirmed. A study in breast
adenocarcinoma showed a strong correlation between HIF-2a and
c-erbB-2 and suggested that this was due to oncogenic rather than
hypoxic activation (Giatromanolaki et al, 2006). To clarify these
issues, measurements of the oxygenation status of gastric cancers
Table 2 Univariate survival analyses
Overall
survival
Disease-specific
survival
Parameter HR 95% CI P
* HR 95% CI P*
HIF-1a
01 — — 1 —
1/2/3/4 1.1 0.8–1.4 0.62 1.0 0.7–1.5 0.82
HIF-1a
Negative 1 — — 1 — —
Focal 0.9 0.5–1.3 0.49 0.7 0.5–1.2 0.26
Invasive edge 1.6 1.0–2.4 0.042 1.6 1.0–2.5 0.047
HIF-2a
0 1.0 — — 1.0 — —
1/2/3/4 1.6 1.1–2.4 0.018 1.6 1.0–2.4 0.038
HIF-1a/HIF-2a
HIF-1a neg/HIF-2a neg 1.0 — — 1.0 — —
HIF-1a pos/HIF-2a neg 1.5 0.8–2.9 0.224 1.1 0.6–2.2 0.76
HIF-1a neg/HIF-2a pos 2.0 1.2–3.6 0.014 1.6 0.9–3.0 0.095
HIF-1a pos/HIF-2a pos 1.8 1.1–3.3 0.036 1.6 0.9–2.9 0.12
HIF-1a/HIF-2a
HIF-2a neg/HIF-1a neg/focal 1.0 — — 1.0 — —
HIF-2a neg/HIF-1a inv 2.1 1.0–4.3 0.37 1.7 0.7–3.7 0.22
HIF-2a pos/HIF-1a neg/focal 1.8 1.1–2.8 0.16 1.5 0.9–2.5 0.10
HIF-2a pos/HIF-1a inv 2.6 1.5–4.6 0.001 2.7 1.5–4.8 0.001
Diff
Well 1.0 — — 1.0 — —
Mod 2.9 1.4–6.2 0.005 3.4 1.3–8.5 0.011
Poor 3.7 1.8–7.8 0.001 5.3 2.1–13.3 0.001
Lauren type
Intestinal 1.0 — — 1.0 — —
Diffuse 1.4 1.0–2.0 0.052 1.8 1.2–2.6 0.003
Location
Non-GOJ 1.0 — — 1.0 — —
GOJ 1.4 1.0–2.0 0.083 1.5 1.0–2.2 0.059
T stage
T0/1 1.0 — — 1.0 — —
T2 2.6 1.0–6.7 0.052 5.2 1.2–22.0 0.023
T3 4.8 1.9–12.0 0.001 9.6 2.3–39.0 0.002
T4 16.8 4.4–64.2 0.0001 37.5 6.8–207.6 0.0001
N stage
N0 1.0 — — 1.0 — —
N1 2.0 1.3–3.0 0.003 2.5 1.5–4.1 0.001
N2 3.5 1.9–6.4 0.0001 4.8 2.5–9.2 0.0001
N3 4.2 1.5–12.0 0.008 5.7 1.9–16.9 0.002
M stage
M0 1.0 — — 1 — —
M1 2.6 1.0–7.1 0.062 2.9 1.1–7.9 0.037
Overall TNM stage
0/1 1.0 — — 1.0 — —
2 1.4 0.8–2.6 0.25 1.8 0.9–3.6 0.12
3 3.3 1.9–5.9 0.0001 4.5 2.3–8.8 0.0001
4 7.6 3.3–17.5 0.0001 10.9 4.4–27.1 0.0001
R class
R0 1.0 — — 1.0 — —
R1 2.3 1.6–3.3 0.0001 2.7 1.8–4.0 0.0001
R2 5.8 2.9–11.6 0.0001 7.2 3.6–14.5 0.0001
CI¼confidence interval; diff¼differentiation; GEJ¼gastro-oesophageal junction;
HIF¼hypoxia-inducible factor; HR¼hazard ratio. *P-value from a univariate Cox-
proportional hazards model. HIF-1a results obtained from Griffiths et al (2007b).
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useful in a number of tumour types (Nordsmark et al, 2003), but
have limited use in gastric cancer because of poor accessibility.
Other approaches such as the immunohistochemical expression of
hypoxia-specific markers such as pimonidazole (Nordsmark et al,
2003) and noninvasive imaging (Koch and Evans, 2003) are being
developed and could be carried out in patients with gastric cancer.
Few studies have assessed both HIF-1a and HIF-2a in relation to
patient outcome. Yoshimura et al (2004) examined 87 surgically
treated patients with colorectal cancer and found that HIF-2a but
not HIF-1a expression predicted prognosis in univariate analysis.
Other studies in nonsmall cell lung cancer and malignant
melanomas showed that HIF-2a expression was related to a poor
outcome when HIF-1a was not (Giatromanolaki et al, 2001, 2003).
These studies confirm the likely tissue-specific differences in the
relative importance of HIF proteins in determining tumour
progression and prognosis.
The expression of HIF-2a was significant in univariate analysis;
however, it was not an independent predictor of prognosis. In view
of the lack of independent prognostic significance, HIF-2a is
unlikely to impact on clinical management. However, the high
expression of HIF-2a in gastric and gastro-oesophageal junction
tumours suggests that it may be of value as a potential therapeutic
target.
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Figure 5 Combined HIF-1a and HIF-2a expression and patient outcome in 168 tumours including noncardia gastric cancers (n¼78) and gastro-
oesophageal junction tumours (n¼90). The first column shows overall survival (A, C, E) and the second column shows disease-specific survival (B, D, F).
HIF¼hypoxia-inducible factor.
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